Inmune Bio, Inc.: insider trades · United States · SEC (Form 4)

About Inmune Bio, Inc.

INmune Bio, Inc. is a US-listed clinical-stage biotechnology company trading on the NASDAQ under the ticker INMB. Headquartered in Boca Raton, Florida, United States, the company is focused on developing immunotherapies that reprogram the innate immune system, with a precision-medicine approach aimed at serious inflammatory and immune-mediated diseases with high unmet medical need. The company was founded in 2015 and was built around the concept of harnessing the body’s innate immune response rather than simply suppressing disease symptoms. ([inmunebio.com](https://www.inmunebio.com/index.php/about-us?utm_source=openai)) INmune Bio originally emerged as an immuno-oncology story and has since expanded into neuroinflammation and rare inflammatory disorders. Its main programs include INKmune, designed to activate NK-cell function in certain hematologic malignancies and solid tumors; INB03, another oncology-oriented asset; and XPro1595, a candidate targeting soluble TNF that has been studied in Alzheimer’s disease and other neuroinflammatory settings. More recently, the company has also highlighted CORDStrom for recessive dystrophic epidermolysis bullosa (RDEB), showing that its platform is being extended beyond oncology and neurology into rare disease biology. ([inmunebio.com](https://www.inmunebio.com/index.php/about-us?utm_source=openai)) From a competitive standpoint, INmune Bio operates in one of the most challenging corners of biotech: clinical-stage development with high cash burn, binary trial outcomes, and strong dependence on regulatory milestones. Its differentiating factor is scientific focus. By targeting innate immunity, the company is positioned differently from many peers that rely more heavily on adaptive immune or broad anti-inflammatory mechanisms. For investors, the name should therefore be viewed as a pipeline-driven biotech story rather than a mature commercial business, with valuation likely to remain highly sensitive to clinical readouts, financing conditions, and regulatory progress. ([inmunebio.com](https://www.inmunebio.com/index.php/about-us?utm_source=openai)) Geographically, INmune Bio is based in Boca Raton, Florida, United States, and also maintains operational capabilities in the United Kingdom through a local manufacturing space lease and related subsidiary activity. That transatlantic footprint reflects the global nature of its clinical and manufacturing strategy. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1711754/000121390026036370/ea0279078-10k_inmune.htm?utm_source=openai)) Recent developments have been centered on 2025 and 2026 business updates. The company reported clinical progress for MINDFuL in Alzheimer’s disease, continued advancement of CORDStrom, and ongoing evaluation of INKmune in prostate cancer. These updates reinforce the picture of a late-stage clinical biotech with meaningful scientific optionality, but also with substantial execution risk, which is typical for small-cap NASDAQ-listed biotech companies in the United States. ([nasdaq.com](https://www.nasdaq.com/press-release/inmune-bio-inc-announces-second-quarter-2025-results-provides-business-update-and?utm_source=openai))